ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintTitle ChevronIcon Twitter
Health Technology

Daiichi Sankyo Co., Ltd.

Business Summary

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2020 JPYUSD
Revenue981,793M9,029.99M
Gross Profit638,587M5,873.37M
Operating income118,028M1,085.55M
Income before tax141,164M1,298.34M
Net income129,074M1,187.15M
EBITDA170,639M1,569.44M
Diluted EPS66.260.60
Dividends Per Share23.330.21
Total Assets2,105.61B19,504.59M
Total liabilities791,549M7,332.21M
Total equity1,305.80B12,095.86M
Operating cash flow196,601M1,808.22M
Currency in JPYCurrency in USD

Historical Data

 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 986,446M 955,124M 960,195M 929,717M 981,793M
Gross Profit 667,824M 605,751M 614,174M 565,112M 638,587M
Operating income 154,054M 127,875M 112,326M 90,461M 118,028M
Income before tax 122,388M 87,788M 81,021M 85,831M 141,164M
Net income 82,282M 53,466M 60,282M 93,410M 129,074M
EBITDA 198,360M 175,248M 159,006M 136,630M 170,639M
Diluted EPS 39.70 26.48 30.36 47.95 66.26
Dividends Per Share 23.33 23.33 23.33 23.33 23.33
Total Assets 1,900.52B 1,914.97B 1,897.75B 2,088.05B 2,105.61B
Total liabilities 666,507M 743,545M 764,709M 838,343M 791,549M
Total equity 1,231.40B 1,175.89B 1,132.98B 1,249.64B 1,305.80B
Operating cash flow 174,281M 136,234M 108,439M 92,033M 196,601M
 Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020
Revenue 8,214.61M 8,820.26M 8,663.48M 8,383.78M 9,029.99M
Gross Profit 5,561.29M 5,593.91M 5,541.46M 5,095.93M 5,873.37M
Operating income 1,282.88M 1,180.88M 1,013.47M 815.73M 1,085.55M
Income before tax 1,019.18M 810.69M 731.02M 773.98M 1,298.34M
Net income 685.20M 493.74M 543.90M 842.33M 1,187.15M
EBITDA 1,651.83M 1,618.35M 1,434.65M 1,232.07M 1,569.44M
Diluted EPS 0.33 0.24 0.27 0.43 0.60
Dividends Per Share 0.19 0.21 0.21 0.21 0.21
Total Assets 16,909.31M 17,185.48M 17,844.41M 18,864.80M 19,504.59M
Total liabilities 5,930.04M 6,672.75M 7,190.49M 7,574.13M 7,332.21M
Total equity 10,956.05M 10,552.78M 10,653.33M 11,290.07M 12,095.86M
Operating cash flow 1,451.32M 1,258.07M 978.40M 829.91M 1,808.22M

Valuation Measures

Mar 2020
PER37.31
ROA6.15%
ROE10.10%
Operating margin12.02%
Profit margin13.14%

Key executives

  • President, CEO & Representative Director: Sunao Manabe
  • CFO, Representative Director & Executive VP: Toshiaki Sai
  • Executive Officer, GM-Research & Development: Wataru Takasaki
  • Director & General Manager-Pharmaceutical Sales: Satoru Kimura
  • Director & Senior Executive Officer: Shoji Hirashima

Shareholders

  • Daiichi Sankyo Co., Ltd. (25.7%)
  • Capital Research & Management Co. (World Investors) (20.7%)
  • Nippon Life Insurance Co. (15.1%)
  • Capital Research & Management Co. (Global Investors) (13.6%)
  • Nomura Asset Management Co., Ltd. (12.1%)
  • The Vanguard Group, Inc. (7.5%)
  • Mizuho Bank Pension Fund (6.0%)
  • Daiwa Asset Management Co. Ltd. (5.5%)
  • Nikko Asset Management Co., Ltd. (5.5%)
  • The Shizuoka Bank, Ltd. (4.8%)

Contact Details

  • Website:http://www.daiichisankyo.co.jp
  • Address: Daiichi Sankyo Head Office Bldg, A&B, 3-5-1 Nihonbashi-honcho, Tokyo, 103-8426, Japan
  • Phone: +81.3.6225.1111

Related Companies

  • Daiichi Sankyo Biotech Co. Ltd.
  • Astellas Pharma, Inc. /3 Drug Products/
  • Daiichi Sankyo Belgium SA
  • Daiichi Sankyo Restricted Stock Compensation Plan
  • Daiichi Sankyo Pharma, Inc.
  • Novare Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Shanghai) Co. Ltd.
  • Daiichi Sankyo Venezuela SA
  • Daiichi Sankyo (Schweiz) AG
  • Daiichi Sankyo Hong Kong Ltd.
  • Daiichi Forging Dalian Co. Ltd.
  • Daiichi Sankyo Pharmaceutical (Beijing) Co. Ltd.
  • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • Daiichi Sankyo Pension Fund
  • Daiichi Sankyo Espha Co., Ltd.
  • Daiichi Sankyo (Thailand) Ltd.
  • Daiichi Sankyo Employee Stock Ownership Plan
  • Daiichi Sankyo (China) Holdings Co., Ltd.
  • Daiichi Sankyo Ireland Ltd.
  • Sankyo Pharma Nederland BV
  • Daiichi Sankyo Taiwan Ltd.
  • NV Sankyo Pharma Belgium SA
  • Daiichi Sankyo Portugal Lda.
  • Daiichi Sankyo Austria GmbH
  • Daiichi Sankyo Nederland BV
  • Daiichi Sankyo Logistics Co. Ltd.
  • Daiichi Sankyo Italia SpA
  • U3 Pharma GmbH
  • Daiichi Sankyo Deutschland GmbH
  • Ranbaxy Europe Ltd.

Competitors

  • AstraZeneca PLC
  • LegoChem Biosciences, Inc.
  • Boryung Pharmaceutical Co., Ltd.
  • Hanmi Pharmaceutical Co., Ltd.
  • Glenmark Pharmaceuticals Limited
  • Assertio Holdings, Inc.
  • Amphastar Pharmaceuticals Inc
  • Forma Therapeutics Holdings, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • Allogene Therapeutics, Inc.
  • ImmunoGen, Inc.
  • Sutro Biopharma, Inc.
  • Deciphera Pharmaceuticals, Inc.
  • CrystalGenomics Inc.
  • Helixmith Co., Ltd.
  • Collegium Pharmaceutical, Inc.
  • Esperion Therapeutics, Inc.
  • Pieris Pharmaceuticals, Inc.
  • Quantum Genomics
  • Springworks Therapeutics, Inc.
  • Agios Pharmaceuticals, Inc.
  • BioDelivery Sciences International, Inc.
  • Aileron Therapeutics, Inc.
  • Aptose Biosciences Inc.
  • Molecular Templates, Inc.
  • Aprea Therapeutics, Inc.
  • Epizyme, Inc.
  • SELLAS Life Sciences Group, Inc.
  • AMAG Pharmaceuticals, Inc.
  • MacroGenics, Inc.
Last Updated on 30 Sep, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more